One of my top holdings had half year results. The shares have very limited newsflow, so I was looking forward to the statement as this is the only time you get an insight in what is going on inside the company. I like the chairman’s statements from them, they are no nonsense, old school type … Continue reading MSI Results today →
Stock Specific update
AMS bid speculation
One of the names which I initiated positions in a couple of months ago(Advanced Medical Solutions) had a bid speculation today. This is not at all surprising as they had one earlier in the year too. Clearly there are a lot of private equity shops lurking around trying to take out solid undervalued UK AIMs … Continue reading AMS bid speculation →
New trade. Ondine Biomedical
Over the last couple of weeks I initiated a position in Ondine Biomedical(OBI). Ondine is a s a Canadian life sciences company focused on developing and commercializing light-based, non-antibiotic antimicrobial therapies to prevent and treat infections in hospitals and other settings. Its core platform, called photodisinfection, uses a photosensitive agent activated by light to rapidly … Continue reading New trade. Ondine Biomedical →
Begbies and FRP
While I no longer hold them, I still follow them closely for potential entry. Both had reasonable updates(revenue growth more than profitability) as the NIC contributions are starting to bite into these labour intensive sectors. I am keenly following what will come out of the budget as there is significant speculation that there will be … Continue reading Begbies and FRP →
Volex half year update(12th of Nov)
Generally good update. The business is doing well in a challenging environment, but the fact that they have production facilities in multiple countries helps a lot with the tariff malarkey. None the less, I sold about 1/3 of my shares on the day, as usually Volex rallies strongly on results and then sells off(I am … Continue reading Volex half year update(12th of Nov) →
Mitie H1 26 trading update
Yesterday(20th Nov), Mitie updated the market with its H1 26 results. I thought the results were excellent (organic revenue growth of 6.4%, overall growth of 10.4%), with all levels growing despite increases in costs(NIC) which I suspect over the long term would roll over into pricing as contracts renew. The pipeline seems excellent(bidding pipeline is … Continue reading Mitie H1 26 trading update →
Hilton Foods
Very disappointing trading update from Hilton Foods. While this has been a long term holding of mine, it is also the one which has gone the most since purchase. This is the second time in a few months that they updated the market negatively. I have a 3 strikes out rule and this is the … Continue reading Hilton Foods →
New trades
Over the past several weeks I’ve done a few more trades. I completely sold out of Alumasc prior to the results(which I am extremely pleased about as it come off by about 20% since then). I think the building business is quite tough in the moment(another one of my holdings Billington had to close down … Continue reading New trades →
Google, Meta and Amazon results
2 out of the 3 beat expectations and the share price action reflected this. While Meta’s core results were great, the significant CAPEX spending on AI is spooking investors. I would likely use this opportunity to top up if the shares drop any further. While I am not a big fan of Google’s Gemini(Open AI … Continue reading Google, Meta and Amazon results →
Proposed changes to NIC contribution for partnerships
There is speculation in the markets today that the UK Chancellor would remove the exemption from the NIC contribution to partnerships and LLPs. This would predominantly affect law and accountancy firms. As a result I have decided to exit my positions in FRP and scale down substantially my Begbies position. On balance the changes should … Continue reading Proposed changes to NIC contribution for partnerships →